https://orcid.org/0000-0001-7201-9163
References
- Miyagawa F. Pathogenesis of paradoxical reactions associated with targeted biologic agents for inflammatory skin diseases. Biomedicines. 2022;10(7):1485.
- Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86(5):1080–1091.
- Munera-Campos M, Ballesca F, Carrascosa JM. Paradoxical reactions to biologic therapy in psoriasis: a review of the literature. Actas Dermosifiliogr. 2018;109(9):791–800.
- Lian N, Zhang L, Chen M. Tumor necrosis factors-α inhibition-induced paradoxical psoriasis: a case series and literature review. Dermatol Ther. 2020;33(6):e14225.
- Lauro W, Picone V, Abategiovanni L, et al. A case of psoriatic alopecia secondary to certolizumab pegol: clinical and trichoscopic evaluation. Int J Dermatol England. 2022. DOI:10.1111/ijd.16275.
- Mihailescu M, Cibull T, Joyce J. Development of drug-induced psoriasiform alopecia in a pediatric patient on ustekinumab. J Cutan Pathol. 2021;48(12):1523–1525.
- Tan TL, Taglia L, Yazdan P. Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy. J Cutan Pathol United States. 2021;48(6):771–774.
- Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol England. 2019;181(3):604–606.
- Kromer C, Schön MP, Mössner R. Eczematous eruption in patients with psoriasis during risankizumab treatment. Eur J Dermatol France. 2020;30(5):599–601.
- Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019;5(2):184–187.
- Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74(6):1153–1159.
- Toussirot É, Aubin F. Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. 2016;2(2):e000239.
- Méry-Bossard L, Bagny K, Chaby G, et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol. 2017;31(1):181–186.
- Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482.
- Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(1):159–169.